|
|
晚期上皮性卵巢癌的药物治疗及进展
|
Abstract:
近年来，可用于上皮性卵巢癌的治疗选择方式不断增加，在化疗的基础上，运用靶向治疗、免疫治疗，以进一步改善卵巢癌患者的预后、提高其生活的质量，就需要制订更加个体化的治疗策略。本文就上皮性卵巢癌化疗、靶向治疗、免疫治疗等方面进行综述，以期为临床提供更多帮助。
In recent years, the treatment options for epithelial ovarian cancer are increasing. On the basis of chemotherapy, targeted therapy and immunotherapy are used to further improve the prognosis of ovarian cancer patients and improve their quality of life, so it is necessary to develop more individ-ualized treatment strategies. This article reviews the chemotherapy, targeted therapy and immu-notherapy of epithelial ovarian cancer, in order to provide more help for clinical practice.
| [1] | Chen, J., Wei, Z., Fu, K., et al. (2022) Non-Apoptotic Cell Death in Ovarian Cancer: Treatment, Resistance and Progno-sis. Biomedicine & Pharmacotherapy, 150, Article ID: 112929. https://doi.org/10.1016/j.biopha.2022.112929 |
| [2] | 马小鸿, 姜洁. 卵巢癌靶向治疗进展[J]. 中国医刊, 2021, 56(4): 352-356. |
| [3] | Kehoe, S., Hook, J., Nankivell, M., et al. (2015) Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. https://doi.org/10.1016/S0140-6736(14)62223-6 |
| [4] | Onda, T., Satoh, T., Saito, T., et al. (2016) Comparison of Treatment Invasiveness between Upfront Debulking Surgery versus Interval Debulking Surgery following Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal, and Peritoneal Cancers in a Phase III Randomised Trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer, 64, 22-31. https://doi.org/10.1016/j.ejca.2016.05.017 |
| [5] | Wang, H., Fan, L., Wu, X., et al. (2022) Efficacy Evaluation of Al-bumin-Bound Paclitaxel Combined with Carboplatin as Neoadjuvant Chemotherapy for Primary Epithelial Ovarian Can-cer. BMC Women’s Health, 22, Article No. 224.
https://doi.org/10.1186/s12905-022-01794-y |
| [6] | Group, I.C.O.N. (2002) Paclitaxel plus Carboplatin versus Standard Chemotherapy with Either Single-Agent Carboplatin or Cyclophosphamide, Doxorubicin, and Cisplatin in Women with Ovarian Cancer: The ICON3 Randomised Trial. The Lancet, 360, 505-515. https://doi.org/10.1016/S0140-6736(02)09738-6 |
| [7] | Aravantinos, G., Fountzilas, G., Kosmidis, P., et al. (2005) Paclitaxel plus Carboplatin versus Paclitaxel plus Alternating Carboplatin and Cisplatin for Initial Treatment of Advanced Ovarian Cancer: Long-Term Efficacy Results: A Hellenic Cooperative Oncology Group (HeCOG) Study. Annals of On-cology, 16, 1116-1122.
https://doi.org/10.1093/annonc/mdi223 |
| [8] | Bookman, M.A., Brady, M.F., McGuire, W.P., et al. (2009) Evalua-tion of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gyneco-logic Cancer Intergroup. Journal of Clinical Oncology, 27, 1419-1425. https://doi.org/10.1200/JCO.2008.19.1684 |
| [9] | Hoskins, P., Vergote, I., Cervantes, A., et al. (2010) Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Car-boplatin-Paclitaxel. Journal of the National Cancer Institute, 102, 1547-1556. https://doi.org/10.1093/jnci/djq362 |
| [10] | Vasey, P.A., Jayson, G.C., Gordon, A., et al. (2004) Phase III Random-ized Trial of Docetaxel-Carboplatin versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma. JNCI: Journal of the National Cancer Institute, 96, 1682-1691. https://doi.org/10.1093/jnci/djh323 |
| [11] | Pignata, S., Scambia, G., Ferrandina, G., et al. (2011) Carboplatin plus Paclitaxel versus Carboplatin plus Pegylated Liposomal Dox-orubicin as First-Line Treatment for Patients with Ovarian Cancer: The MITO-2 Randomized Phase III Trial. Journal of Clinical Oncology, 29, 3628-3635. https://doi.org/10.1200/JCO.2010.33.8566 |
| [12] | Katsumata, N., Yasuda, M., Isonishi, S., et al. (2013) Long-Term Results of Dose-Dense Paclitaxel and Carboplatin versus Conventional Paclitaxel and Carboplatin for Treatment of Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (JGOG 3016): A Randomised, Controlled, Open-Label Trial. The Lancet Oncology, 14, 1020-1026.
https://doi.org/10.1016/S1470-2045(13)70363-2 |
| [13] | Chan, J.K., Brady, M.F. and Monk, B.J. (2016) Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer. The New England Journal of Medicine, 374, 2603-2604. https://doi.org/10.1056/NEJMc1603849 |
| [14] | Pignata, S., Scambia, G., Katsaros, D., et al. (2014) Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 396-405. https://doi.org/10.1016/S1470-2045(14)70049-X |
| [15] | Blagden, S.P., Cook, A.D., Poole, C., et al. (2020) Weekly Platinum-Based Chemotherapy versus 3-Weekly Platinum-Based Chemotherapy for Newly Diagnosed Ovarian Cancer (ICON8): Quality-Of-Life Results of A Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 969-977. https://doi.org/10.1016/S1470-2045(20)30218-7 |
| [16] | Yang, X. and Fu, C. (2022) The Potential Feasibility of Nab-Paclitaxel as the First-Line Chemotherapy for Ovarian Cancer: Clinical Development and Future Perspectives. Ar-chives of Gynecology and Obstetrics, 306, 1417-1429.
https://doi.org/10.1007/s00404-022-06425-3 |
| [17] | Wang, L., Li, S., Zhu, D., et al. (2023) Effectiveness and Safety of Nab-Paclitaxel and Platinum as First-Line Chemotherapy for Ovarian Cancer: A Retrospective Study. Journal of Gy-necologic Oncology, 34, e44.
https://doi.org/10.3802/jgo.2023.34.e44 |
| [18] | Dou, Y. and Jiang, D. (2021) Research Progress of Small Molecule Anti-Angiogenic Drugs in Non-Small Cell Lung Cancer. Chinese Journal of Lung Cancer, 24, 56-62. |
| [19] | Perren, T.J., Swart, A.M., Pfisterer, J., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. https://doi.org/10.1056/NEJMoa1103799 |
| [20] | Oza, A.M.P., Cook, A.D.M., Pfisterer, J.P., et al. (2015) Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. The Lancet Oncology, 16, 928-936. https://doi.org/10.1016/S1470-2045(15)00086-8 |
| [21] | Burger, R.A., Brady, M.F., Bookman, M.A., et al. (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. The New England Journal of Medicine, 365, 2473-2483. https://doi.org/10.1056/NEJMoa1104390 |
| [22] | Tewari, K.S., Burger, R.A., Enserro, D., et al. (2019) Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clin-ical Oncology, 37, 2317-2328.
https://doi.org/10.1200/JCO.19.01009 |
| [23] | Garcia Garcia, Y., De Juan Ferré, A., Mendiola, C., et al. (2019) Effi-cacy and Safety Results from GEICO 1205, a Randomized Phase II Trial of Neoadjuvant Chemotherapy with or without Bevacizumab for Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 29, 1050-1056. https://doi.org/10.1136/ijgc-2019-000256 |
| [24] | Rouzier, R., Gouy, S., Selle, F., et al. (2017) Efficacy and Safety of Bevacizumab-Containing Neoadjuvant Therapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer: Results from the ANTHALYA Trial. European Journal of Cancer, 70, 133-142. https://doi.org/10.1016/j.ejca.2016.09.036 |
| [25] | Moore, K., Colombo, N., Scambia, G., et al. (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medicine, 379, 2495-2505.
https://doi.org/10.1056/NEJMoa1810858 |
| [26] | Pujade-Lauraine, E., Ledermann, J.A., Selle, F., et al. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet On-cology, 18, 1274-1284.
https://doi.org/10.1016/S1470-2045(17)30469-2 |
| [27] | Gonzalez-Martin, A., Pothuri, B., Vergote, I., et al. (2019) Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medicine, 381, 2391-2402. https://doi.org/10.1056/NEJMoa1910962 |
| [28] | Moore, K.N., Secord, A.A., Geller, M.A., et al. (2019) Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 20, 636-648.
https://doi.org/10.1016/S1470-2045(19)30029-4 |
| [29] | Varga, A., Piha-Paul, S., Ott, P.A., et al. (2019) Pembroli-zumab in Patients with Programmed Death Ligand 1—Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152, 243-250.
https://doi.org/10.1016/j.ygyno.2018.11.017 |
| [30] | Uyar, D., Michener, C.M., Bradley, W.H., et al. (2020) Prelimi-nary Results from Phase II Trial of Pembrolizumab with First Line Platinum Based Chemotherapy followed by Mainte-nance Pembrolizumab for Patients with Suboptimally Cytoreduced Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 159, 146-147.
https://doi.org/10.1016/j.ygyno.2020.05.202 |
| [31] | Westin, S.N., Moore, K., Chon, H.S., et al. (2023) Durvalumab plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab with or without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. Journal of Clinical Oncology, 42, 283-299. |
| [32] | Gaillard, S., Duska, L., Broadwater, G., et al. (2021) AdoRN Trial: Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer. Gy-necologic Oncology, 162, S61. https://doi.org/10.1016/S0090-8258(21)00757-5 |
| [33] | Kako, T., Dholakia, J., Leath, C., et al. (2022) Single-Arm Phase II Trial of Carboplatin and Mirvetuximab Soravtansine as Neoadjuvant Chemotherapy (NACT) for Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (EOC) Who Are Folate Receptor α Positive (NCT04606914) (578). Gynecologic Oncology, 166, S281.
https://doi.org/10.1016/S0090-8258(22)01798-X |
| [34] | Ray-Coquard, I., Pautier, P., Pignata, S., et al. (2019) Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England Journal of Medicine, 381, 2416-2428. https://doi.org/10.1056/NEJMoa1911361 |
| [35] | Mirza, M.R., Bergmann, T.K., Mau-Sorensen, M., et al. (2019) A Phase I Study of the PARP Inhibitor Niraparib in Combination with Bevacizumab in Platinum-Sensitive Epi-thelial Ovarian Cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 84, 791-798. https://doi.org/10.1007/s00280-019-03917-z |
| [36] | Zhu, X. and Lang, J. (2017) Programmed Death-1 Pathway Blockade Produces a Synergistic Antitumor Effect: Combined Application in Ovarian Cancer. Journal of Gynecologic Oncology, 28, e64.
https://doi.org/10.3802/jgo.2017.28.e64 |
| [37] | Konstantinopoulos, P.A., Waggoner, S., Vidal, G.A., et al. (2019) Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Plati-num-Resistant Ovarian Carcinoma. JAMA Oncology, 5, 1141-1149. https://doi.org/10.1001/jamaoncol.2019.1048 |
| [38] | Domchek, S.M., Postel-Vinay, S., Im, S.A., et al. (2020) Olaparib and Durvalumab in Patients with Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1/2, Basket Study. Lancet Oncology, 21, 1155-1164. https://doi.org/10.1016/S1470-2045(20)30324-7 |
